Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoLazer: Neoadjuvant lazertinib with or without chemotherapy for EGFR-mutated resectable NSCLC
KCT0009313Phase 2Not yet recruiting
- Sponsor
- Yuhan
- Start
- Mar 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC), sponsored by Yuhan. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0009313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009313.